Aaron Thomson

Steven Silver

- **bioAffinity Technologies, Inc.** announced on **October 16, 2025**, that it received a notification of allowance from the United States Patent and Trademark Office (USPTO) for a new patent.  **[1712762_0001493152-25-018267_form8-k.htm:0]** **[1712762_0001493152-25-018267_ex99-1.htm:0]** **[1712762_0001493152-25-018267_form8-k.htm:1]** 
- The patent covers an **AI-built algorithm and flow cytometry platform** used in the company's **CyPath® Lung** test for detecting early-stage lung cancer.  **[1712762_0001493152-25-018267_ex99-1.htm:0]** 
- This allowance expands bioAffinity's global patent estate to **18 awarded and 33 pending patents**.  **[1712762_0001493152-25-018267_ex99-1.htm:0]**

bioAffinity Technologies announces U.S. patent allowance for lung cancer diagnostic algorithm

- **bioAffinity Technologies, Inc. (BIAF)** announced on **October 15, 2025**, that it has **regained compliance** with all Nasdaq continued listing requirements.  **[1712762_0001493152-25-018093_ex99-1.htm:0]** 
- The company now meets the Nasdaq Listing Rule 5550(a)(2) for a minimum closing bid price of **$1.00 per share** and Nasdaq Listing Rule 5550(b)(1) for a minimum of **$2.5 million in stockholders' equity**.  **[1712762_0001493152-25-018093_ex99-1.htm:0]** **[1712762_0001493152-25-018093_form8-k.htm:1]** 
- As a result, bioAffinity Technologies' common stock (BIAF) and warrants (BIAFW) will continue to trade on the Nasdaq Capital Market.  **[1712762_0001493152-25-018093_ex99-1.htm:0]** 
- Nasdaq has imposed a **one-year Mandatory Panel Monitor**, during which any failure to comply with the Equity Rule will not grant additional time to regain compliance, though a new hearing can be requested before delisting.  **[1712762_0001493152-25-018093_ex99-1.htm:0]** **[1712762_0001493152-25-018093_form8-k.htm:1]**

bioAffinity Technologies Regains Nasdaq Listing Compliance

- bioAffinity Technologies, Inc. announced the closing of a registered direct offering on **October 9, 2025**, raising approximately **$1.8 million** in gross proceeds.  **[1712762_0001493152-25-017627_ex99-2.htm:0]** **[1712762_0001493152-25-017627_form8-k.htm:1]** 
- The offering involved the sale of **720,000 shares** of common stock at a price of **$2.50 per share**.  **[1712762_0001493152-25-017627_ex99-1.htm:0]** **[1712762_0001493152-25-017627_ex99-2.htm:0]** 
- The company plans to use the net proceeds for **working capital**, to support sales of its noninvasive lung cancer test **CyPath® Lung**, and for **general corporate purposes**.  **[1712762_0001493152-25-017627_ex99-2.htm:1]** 
- As part of the agreement, bioAffinity Technologies will not issue common stock or equivalents until **November 14, 2025**, and its officers and directors are subject to **60-day lock-up agreements** from the closing date.  **[1712762_0001493152-25-017627_form8-k.htm:1]** **[1712762_0001493152-25-017627_ex10-1.htm:32]**

bioAffinity Technologies Announces Closing of $1.8 Million Registered Direct Offering

- **bioAffinity Technologies** closed a previously announced **registered direct offering** of **720,000 shares** of common stock at a purchase price of **$2.50 per share**.  **[1712762_20251009NY94613:0]** 
- The offering was priced at-the-market under Nasdaq rules.  **[1712762_20251009NY94613:0]** 
- The company intends to use the net proceeds for **working capital**, to support expected growing sales for **CyPath® Lung**, and for general corporate purposes.  **[1712762_20251009NY94613:0]** 
- **WallachBeth Capital LLC** acted as the sole placement agent for the offering.  **[1712762_20251009NY94613:0]**

bioAffinity Technologies Closes $1.8M Registered Direct Offering

- bioAffinity Technologies, Inc. announced that sales of its CyPath® Lung diagnostic test for lung cancer reached a **new high** in the **third quarter of 2025**.  **[1712762_0001493152-25-017328_ex99-1.htm:0]** **[1712762_0001493152-25-017328_form8-k.htm:1]** 
- This record volume represents a **95% increase** over the previous quarter and a **97% rise** in sales for the first nine months of 2025 compared to the same period in 2024.  **[1712762_0001493152-25-017328_ex99-1.htm:0]** 
- The growth is attributed to increased adoption by Veterans’ hospitals and market expansion in the mid-Atlantic region, alongside a **77% increase** in new patients and improved patient compliance for at-home sample collection in Q3 2025.  **[1712762_0001493152-25-017328_ex99-1.htm:0]**

bioAffinity Technologies Reports Record CyPath® Lung Test Volume in Q3 2025

- **bioAffinity Technologies** announced the **closing** of a public offering on **September 30, 2025**, generating **aggregate gross proceeds of $4.8 million**.  **[1712762_0001493152-25-016366_ex99-2.htm:0]** 
- The offering consisted of **1,921,761 shares** of Common Stock (or pre-funded warrants) at a purchase price of **$2.50 per share** (or $2.493 per Pre-Funded Warrant).  **[1712762_0001493152-25-016366_ex99-2.htm:0]** 
- As of September 30, 2025, after the closing of this offering and the exercise of certain Pre-Funded Warrants, there are **3,100,402 shares of Common Stock outstanding**.  **[1712762_0001493152-25-016366_form8-k.htm:3]** 
- The company believes it has regained compliance with Nasdaq's Continued Listing Equity Requirement, with stockholders' equity exceeding **$2,500,000**, partly due to this offering and a **1-for-30 reverse stock split** that became effective on September 18, 2025.  **[1712762_0001493152-25-016366_form8-k.htm:4]**

bioAffinity Technologies Closes $4.8 Million Public Offering

- bioAffinity Technologies, Inc. **closed a public offering** of securities, generating **$4.8 million** in aggregate gross proceeds before deducting agent fees and other estimated expenses.  **[1712762_20250930NY87166:0]** 
- The offering consisted of **1,921,761 shares** of Common Stock (or pre-funded warrants) at a purchase price of **$2.50 per share** (or **$2.493 per Pre-Funded Warrant**).  **[1712762_20250930NY87166:0]** 
- **WallachBeth Capital LLC** served as the sole placement agent for the offering.  **[1712762_20250930NY87166:0]**

bioAffinity Technologies Closes Public Offering

- bioAffinity Technologies, Inc. (BIAF) announced a **1-for-30 reverse stock split** of its common stock.  **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]** 
- The reverse stock split will become effective on **September 18, 2025, at 4:01 p.m. Eastern Time**, with trading on a split-adjusted basis commencing on **September 19, 2025** on the Nasdaq Capital Market.  **[1712762_0001493152-25-013892_ex3-1.htm:0]** **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]** 
- The primary purpose of the reverse stock split is to **comply with Nasdaq's minimum bid price requirement**.  **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]** 
- Following the split, the company will have approximately **1,338,029 shares of common stock issued and outstanding**, and stockholders will receive **cash in lieu of fractional shares**.  **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]**

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split

- On **September 3, 2025**, bioAffinity Technologies, Inc. announced that its **CyPath® Lung** diagnostic test was featured in **U.S. Medicine Magazine**, highlighting its potential to improve lung cancer detection and lower costs for the Department of Veterans Affairs (VA).  **[1712762_0001641172-25-026403_ex99-1.htm:0]** **[1712762_0001641172-25-026403_form8-k.htm:1]** 
- Research published in the Journal of Health Economics and Outcomes Research (JHEOR) indicated that integrating CyPath® Lung into the standard of care could have resulted in savings of nearly **$895 million for private payers** and **$379 million for Medicare** in 2022, primarily by reducing follow-up diagnostic assessments and procedures.  **[1712762_0001641172-25-026403_ex99-1.htm:0]** 
- Clinical study results demonstrated that CyPath® Lung achieved **92% sensitivity**, **87% specificity**, and **88% accuracy** in detecting lung cancer in high-risk patients with small lung nodules (less than 20 mm).  **[1712762_0001641172-25-026403_ex99-1.htm:0]** **[1712762_0001641172-25-026403_ex99-1.htm:1]**

bioAffinity Technologies (BIAF)